Gene Therapy Trials Show Positive Results in Sickle Cell Disease and Thalassemia
Results from two early-phase trials suggest that CRISPR-Cas12a gene editing has the potential to cure sickle cell disease and transfusion-dependent beta-thalassemia.
Results from two early-phase trials suggest that CRISPR-Cas12a gene editing has the potential to cure sickle cell disease and transfusion-dependent beta-thalassemia.
and they’re trying to sell it for a billion dollarsbloomberg feature on Chase Herro: https://www.bloomberg.com/news/features/2024-09-13/behind-the-trump-cryp…
A study found that adding depression to Life’s Essential 8 provides minimal improvements in predicting cardiovascular and all-cause mortality risk.
Two different bubbles and two completely different revenue streams mean only one thing.
Click on the article title to read more.
This qualitative study develops a schema to classify and describe the breadth of cannabis products commercially available in the US.
International medical graduates (IMGs) have faced bias for decades. A prominent IMG physician says advocacy is the way to change that.
Cleveland Clinic’s Director of Ophthalmic Oncology explains how to tell the difference between an iris freckle, mole and melanoma.
A coalition of 12 Philadelphia-area health systems have abandoned the use of race adjustments in four clinical tools
Brazilian pharmaceutical company EMS has offered to join forces with rival Hypera to create the country’s biggest drug manufacturer, they said on Monday.
The affiliation will enable One Medical members to access specialty care at Cleveland Clinic via patient referrals, the organizations said.